-
-
-
-
-
-
-
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
-
-
-
-
-
-
-
Magdalena Biosciences coca extract prevents weight gain in mice
-
-
-
-
-
-
-
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
-
-
-
-
-
-
-
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA)
-
-
-
-
-
-
-
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
-
-
-
-
-
-
-
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
-
-
-
-
-
-
-
Magdalena Biosciences begins preclinical study of coca for appetite control
-
435,289 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

